sorafenib has been researched along with Thyroid Neoplasms in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (8.10) | 29.6817 |
| 2010's | 154 (73.33) | 24.3611 |
| 2020's | 39 (18.57) | 2.80 |
| Authors | Studies |
|---|---|
| Farias, EC; Hoff, AO | 1 |
| Antonelli, A; Benvenga, S; Elia, G; Fallahi, P; Ferrari, SM; Mazzi, V; Paparo, SR; Ragusa, F; Ulisse, S | 1 |
| Hamada, K; Kazakova, D; Kurashige, T; Nagayama, Y; Shimamura, M | 1 |
| Alevizaki, M; Karapanou, O; Saltiki, K; Simeakis, G; Vlassopoulou, B | 1 |
| Cătoi, AF; Georgescu, CE; Lozovanu, V; Nasui, BA; Pop, C; Silaghi, CA; Silaghi, H | 1 |
| Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T | 1 |
| Abu-Sini, H; Billan, S; Taha, T | 1 |
| Caterino, M; Ciardiello, F; Facchini, S; Fasano, M; Lo Giudice, G; Pirozzi, M; Rauso, R; Sica, A; Varriale, E; Zotta, A | 1 |
| Cheng, SP; Huang, SS; Kuo, CY; Li, YS; Tsai, CH | 1 |
| Alavianmehr, A; Dabbaghmanesh, MH; Emadi, L; Farjadian, S; Jonaidi, H; Kalani, M; Talezadeh Shirazi, P | 1 |
| Desar, IME; Doorn, LV; Eskens, FALM; Groenland, SL; Guchelaar, NAD; Huitema, ADR; Koolen, SLW; Mathijssen, RHJ; Steeghs, N; van Eerden, RAG; van Erp, NP | 1 |
| Alevizaki, M; Babajanyan, S; Bowles, DW; Brose, MS; Guan, R; Huang, SM; Lamartina, L; Lin, CC; Ozgurdal, K; Peeters, RP; Pitoia, F; Rumyantsev, P; Shen, DH; Smit, JWA; Sugitani, I; Takahashi, S; Tori, M; Tsai, HJ; Worden, F | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, SY; Lee, JH; Lim, JH; Pan, CH; Park, K; Park, KC; Weicker, R; Yun, HJ | 1 |
| Castelo, B; Zafón, C | 1 |
| Herranz, UA | 1 |
| Basté Rotllan, N | 1 |
| Chen, Y; Hao, J; Hu, L; Li, H; Lin, Q; Xie, W; Yun, X; Zeng, Y | 1 |
| Lin, S; Lu, J; Su, J; Wang, M; Yan, J; Zhang, J | 1 |
| Bartsch, DK; Di Fazio, P; Holzer, K; Keber, C; Knauff, F; Manoharan, J; Maurer, E; Roth, S; Wächter, S | 1 |
| Jeon, MJ; Jin, M; Kim, BH; Kim, EY; Kim, M; Kim, WB; Kim, WG; Lim, DJ; Shin, DY; Shong, YK | 1 |
| Dongmei, H; Jingtai, Z; Linfei, H; Ning, K; Tianze, Z; Wei, W; Weiwei, Y; Xiangqian, Z; Xiangrui, M; Xianhui, R; Xin, W; Xinwei, Y; Yuyang, Q | 1 |
| Chang, HJ; Chang, HS; Kim, Y; Lee, SY; Park, KC; Yun, HJ | 1 |
| Akhanlı, P; Bayır, Ö; Çakal, E; Düğer, H; Kertmen, H; Kızılgül, M; Korkmaz, MH; Saylam, G; Sencar, ME; Uçan, B; Yazılıtaş, D; Yılmazer, D | 1 |
| Bai, Y; Deng, Z; Li, Z; Liu, C; Liu, P; Liu, Y; Lv, J; Lv, L; Zhang, L; Zhang, M; Zou, H | 1 |
| Chen, P; Feng, H; Ling, Y; Long, M; Luo, J; Ouyang, W; Pan, L; Xiong, X; Zou, Q | 1 |
| Berglund, H; Hariri, M; Malmberg, C; Mortensen, ACL; Papalanis, E; Spiegelberg, D | 1 |
| Chen, WY; Chou, TC; Lee, YY; Lin, SF; Lu, YL; Wong, RJ; Wu, MH; Yeh, CN | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, Y; Lee, JH; Park, KC; Weicker, R; Yun, HJ | 1 |
| Asano, Y; Ishihara, S; Kashiwagi, S; Morisaki, T; Noda, S; Ohira, M; Onoda, N; Takashima, T; Tauchi, Y | 1 |
| Chung, JH; Kim, BH; Kim, EY; Kim, M; Kim, TH; Kim, WB; Kim, WG; Lim, DJ; Oh, HS; Park, SY; Shin, DY; Shong, YK | 1 |
| Iwasaki, H; Masudo, K; Nakayama, H; Sakai, R; Suganuma, N; Takasaki, H; Toda, S; Yamazaki, H | 1 |
| Ahn, J; Jeon, MJ; Kim, TY; Kim, WB; Kim, WG; Shong, YK; Song, E | 1 |
| Abballe, L; Allegri, L; Bulotta, S; Celano, M; Damante, G; Maggisano, V; Pecce, V; Russo, D | 1 |
| Beale, S; Boland, A; Chaplin, M; Duarte, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Houten, R; Shenoy, A | 1 |
| Bagust, A; Beale, S; Boland, A; Duarte, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Hounsome, J; Houten, R; Richardson, M; Shenoy, A | 1 |
| Feng, G; Luo, Y; Xu, J; Zeng, F; Zhang, Q; Zhu, J | 1 |
| Chen, L; Cheng, L; Fu, H; Jin, Y; Sa, R | 1 |
| Chang, CT; Chang, JS; Hsieh, TC; Huang, SM; Huang, YH; Hung, CJ; Hung, CL; Lin, CY; Tsai, HJ; Yang, HR | 1 |
| Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A | 1 |
| Chang, H; Chang, HS; Kim, SM; Kim, SY; Lee, YS; Park, CS | 1 |
| Costante, G | 1 |
| Amthauer, H; Binse, I; Brink, I; Buck, A; Darr, A; Dierks, C; Koch, C; König, U; Kreissl, MC; Luster, M; Reuter, C; Scheidhauer, K; Schott, M; Verburg, FA; Willenberg, HS; Zielke, A | 1 |
| Chou, TC; Huang, YT; J Wong, R; Lin, SF; Lu, YL; Wu, MH | 1 |
| Cao, V; Chen, L; Huang, W; Ting, J; Wilson, L | 1 |
| Li, L; Long, B; Yan, F; Yang, Y; Ye, T; Ye, X; Yi, H; Zhang, L | 1 |
| Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I | 1 |
| Baxi, SS; Cullen, G; Dunn, LA; Fagin, JA; Fury, MG; Ghossein, RA; Haque, S; Ho, AL; Pfister, DG; Sherman, EJ; Sima, CS | 1 |
| Chiba, T; Hara, H; Ishii, J; Kamma, H; Sawa, A; Yamamoto, H | 1 |
| Pacini, F | 1 |
| Agate, L; Bottici, V; Cappagli, V; Danesi, R; Del Re, M; Elisei, R; Giani, C; Lorusso, L; Matrone, A; Molinaro, E; Pieruzzi, L; Puleo, L; Valerio, L; Viola, D | 1 |
| Arvat, E; Berardelli, R; Felicetti, F; Gallo, M; Marchisio, F; Nervo, A; Piovesan, A | 1 |
| Ge, M; Jin, S; Li, L; Long, B; Yang, M; Ye, T; Ye, X; Yi, H; Zhang, L | 1 |
| García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
| Chung, JH; Kim, BH; Kim, EY; Kim, M; Kim, TH; Kim, WB; Kim, WG; Lim, DJ; Shin, DY; Shong, YK | 1 |
| Cagan, RL; Dar, AC; Maldonado, AY; Murray, MA; Real, A; Schlessinger, A; Scopton, AP; Silber, L; Sonoshita, M; Ung, PMU | 1 |
| Avenia, N; Ayroldi, E; Cannarile, L; Cari, L; Marchetti, MC; Moretti, S; Petrillo, MG; Puxeddu, E; Riccardi, C; Ricci, E; Ronchetti, S | 1 |
| Bassam, A; Garai, I; Horváth, Z; Kocsis, J; Mezősi, E; Nagy, E; Pápai, Z; Rubovszky, G; Rucz, K; Szekanecz, É; Uhlyarik, A; Uray, I | 1 |
| Burnett, H; Cheng, W; Copher, R; Guyot, P; Li, X; Makin, C; Tremblay, G | 1 |
| Aizic, A; Fliss, DM; Izkhakov, E; Knoll, E; Kohen, F; Sharon, O; Somjen, D; Stern, N | 1 |
| Chayahara, N; Goto, H; Hirokawa, M; Imamura, Y; Ito, Y; Kasahara, T; Kiyota, N; Minami, H; Miya, A; Miyauchi, A; Mukohara, T; Nagatani, Y; Nibu, KI; Otsuki, N; Suto, H; Toyoda, M | 1 |
| Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB | 1 |
| Chou, TC; Hsueh, C; Lin, JD; Lin, SF; Wong, RJ | 1 |
| Beckham, TH; Brinkman, T; Fagin, JA; Groen, AH; Lee, NY; McBride, S; Riaz, N; Romesser, PB; Sabol, C; Sabra, M; Shaha, AR; Sherman, EJ; Spielsinger, D; Tsai, CJ; Tuttle, RM; Wong, RJ | 1 |
| Cury-Martins, J; Domingues, RB; Macarenco, R; Sanches, JA; Sato-Sano, M; Vasconcelos, R | 1 |
| Escudier, B; Kudo, M; Worden, F | 1 |
| Ke, Y; Xiang, C | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| García Falcone, MG; Jerkovich, F; Pitoia, F | 1 |
| Adejoro, O; Chatterjee, D; Copher, R; Dacosta Byfield, SA; Joshi, PR; Worden, FP | 1 |
| Austin, R; Brose, MS; Grevel, J; Huang, F; Jentsch, G; Lettieri, J; Meinhardt, G; Mitchell, D; Peña, CEA; Ploeger, BA; Prins, NH; Schlumberger, M | 1 |
| Cho, SW; Hwangbo, Y; Kim, MJ; Kim, SM; Lee, EK; Lee, Y; Lee, YJ; Park, DJ; Park, YJ | 1 |
| Dai, J; Wang, Z; Yan, J; Yin, Z; Zhang, Y | 1 |
| Benekli, M; Capdevila, J; Ho, ATN; Katoh, R; Kondo, T; Nakazawa, T; Tran, TTK; Vuong, HG | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
| Brown, SR; Buckley, HL; Du, Y; Farnell, K; Flanagan, L; Flux, G; Gonzalez de Castro, D; Gregory, R; Hall, A; Moss, L; Newbold, K; Wadsley, J | 1 |
| Alghuzlan, A; Bardet, S; Borget, I; Borson Chazot, F; de la Fouchardiere, C; Do Cao, C; Godbert, Y; Leboulleux, S; Leenhardt, L; Zerdoud, S | 1 |
| Chockalingam, R; Huen, A; Morse, DC; Pye, A | 1 |
| Ewig, JM; Iyer, P; Mayer, JL | 1 |
| Banzo, I; Carril, JM; Martínez-Rodríguez, I | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S | 1 |
| Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM | 1 |
| Luo, QY; Qiu, ZL; Shen, CT | 2 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Bellesoeur, A; Billemont, B; Blanchet, B; Carton, E; Clerc, J; Goldwasser, F; Groussin, L; Mir, O | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Barroso-Sousa, R; Evangelista, J; Fragoso, MC; Hoff, AO; Kulcsar, MA; Lerario, AM; Lin, CS; Lourenço, DM; Papadia, C | 1 |
| Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L | 1 |
| Busaidy, NL; Cabanillas, ME; Cote, GJ; Dadu, R; Devine, C; Habra, MA; Hernandez, M; Hu, MI; Jimenez, C; Sellin, RV; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
| Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y | 1 |
| Pitoia, F | 1 |
| Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
| Haraldsdottir, S; Shah, MH | 1 |
| Bastholt, L; Brose, MS; Chung, J; de la Fouchardiere, C; Elisei, R; Jarzab, B; Kappeler, C; Molnár, I; Nutting, CM; Pacini, F; Paschke, R; Peña, C; Schlumberger, MJ; Sherman, SI; Shong, YK; Siena, S; Smit, JW | 1 |
| Ito, K; Sugino, K; Takami, H | 1 |
| Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
| Giusti, M; Minuto, F; Monti, E; Morbelli, S; Mortara, L; Pera, G; Sambuceti, G | 1 |
| Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C | 1 |
| Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN | 1 |
| Arvat, E; Castiglione, A; Ciccone, G; Felicetti, F; Gallo, M; Michelon, F; Nervo, A; Piovesan, A; Viansone, AA; Zichi, C | 1 |
| Becherer, A; Dierneder, J; Gallowitsch, H; Hoffmann, M; Lind, P; Lindner, C; Lipp, R; Niederle, B; Pall, G; Pirich, C; Raderer, M; Romeder, F; Virgolini, I | 1 |
| Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ | 1 |
| Handkiewicz-Junak, D; Jarzab, B; Krajewska, J | 1 |
| Colevas, AD; Gruber, JJ | 1 |
| Barceló-Batllori, S; Bell, O; Corra, M; de Leiva, A; González, C; Lerma, E; Mato, E; Moral, A; Orera, I; Pérez, JI; Selva, L | 1 |
| Cohen, MS; White, PT | 1 |
| Chen, G; Derwahl, M; Nicula, D; Renko, K | 1 |
| Blair, HA; Plosker, GL | 1 |
| Colao, A; Faggiano, A; Marotta, V | 1 |
| Chen, L; Dong, Q; Liu, M; Ruan, M | 1 |
| Britten, M; Broecker-Preuss, M; Fuhrer, D; Mann, K; Müller, S; Schmid, KW; Worm, K | 1 |
| Karedan, T; Perez, CA; Wang, E | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| Agulnik, M; Carneiro, BA; Carneiro, RM; Giles, FJ; Kopp, PA | 1 |
| Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Mazzi, V; Miccoli, M; Miccoli, P; Politti, U; Ulisse, S | 1 |
| Antonelli, A; Baldini, E; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Politti, U; Spisni, R; Ulisse, S | 1 |
| Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A | 1 |
| Byrd, JC; Caligiuri, MA; Campbell, AR; Carson, WE; Fairchild, ET; Grignol, VP; Guenterberg, KD; Jaime-Ramirez, AC; Karpa, VI; Kondadasula, SV; Lesinski, GB; Levine, KM; Mace, TA; Markowitz, J; Martin del Campo, SE; McClory, S; Monk, JP; Mortazavi, A; Mundy-Bosse, BL; Olencki, TE; Pan, X; Paul, BK; Shah, MH; Tridandapani, S; Trikha, P | 1 |
| Kiyota, N | 1 |
| Chen, W; Lv, Y; Xie, R; Yu, J; Zhang, J | 1 |
| Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C | 1 |
| Covell, LL; Ganti, AK | 1 |
| Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW | 1 |
| Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F | 1 |
| Wirth, LJ | 1 |
| Cai, J; Ye, X; Zhu, Y | 1 |
| de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR | 1 |
| Fiskus, W; Mitsiades, N | 1 |
| Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T | 1 |
| de la Fouchardière, C | 2 |
| Jaffry, A; Jean, GW; Khan, SA; Mani, RM | 1 |
| Okano, S | 1 |
| Brose, MS; Chen, EY; Cohen, AB; Feldman, MD; Johnson, BA; Ma, C; Pappas-Paxinos, M; Stopenski, SJ; Tang, W; Troxel, AB; Yarchoan, M | 1 |
| Jerkovich, F; Pitoia, F | 1 |
| Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
| Abdulghani, J; Cooper, T; Derr, J; Dicker, D; El-Deiry, WS; Finnberg, NK; Gallant, JN; Gokare, P; Goldenberg, D; Liao, J; Liu, J; Whitcomb, T | 1 |
| Jarzab, B; Krajewska, J; Kukulska, A | 1 |
| Basu, S; Joshi, A | 1 |
| Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I | 1 |
| Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS | 1 |
| Fountas, A; Giotaki, Z; Kalogeropoulos, CD; Tigas, S; Tsatsoulis, A | 1 |
| Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M | 1 |
| Brose, MS; Flaherty, KT; Gupta-Abramson, V; Loevner, LA; Mandel, SJ; Nellore, A; O'Dwyer, PJ; Puttaswamy, K; Ransone, K; Redlinger, M; Troxel, AB | 1 |
| Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
| Ahn, SH; Clayman, GL; Henderson, YC; Kang, Y | 1 |
| Lohse, AW; Schramm, C; Schuch, G | 1 |
| Arbogast, D; Collamore, M; Grever, M; Hall, NC; King, M; Kloos, RT; Knopp, MV; Liang, J; Ringel, MD; Rittenberry, J; Saji, M; Shah, MH; Stevens, R; Vasko, VV; Wakely, PE; Wei, L; Wright, JJ | 1 |
| Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
| Goldfarb, M; Hodin, R; Nucera, C; Parangi, S | 1 |
| Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM | 1 |
| Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K | 1 |
| Figueiredo, J; Gonçalves, J; Meireles, AM; Preto, A; Rebocho, AP; Rocha, AS; Seca, H; Seruca, R; Soares, P; Sobrinho-Simões, M; Vasconcelos, HM | 1 |
| Sherman, SI | 2 |
| Alfano, RW; Bugge, TH; Duesbery, NS; Frankel, AE; Lairmore, TC; Leppla, SH; Liu, S; Mitchell, IC; Nwariaku, F; Ortiz, JM | 1 |
| Brose, MS; Cohen, MA; Keefe, SM | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Chon, SY; Diamantis, ML | 1 |
| Arbogast, D; Collamore, M; Hall, NC; Kloos, RT; Knopp, MV; Lam, ET; Liang, J; Moley, JF; Prior, TW; Ringel, MD; Saji, M; Sammet, S; Shah, MH; Snyder, PJ; Vasko, VV; Villalona-Calero, MA; Wakely, PE; Wei, L; Wright, JJ | 1 |
| Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
| Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ | 1 |
| Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
| Dralle, H; Machens, A | 1 |
| Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F | 1 |
| De Falco, V; Jo, YS; Kim, DW; Kim, JM; Kim, SJ; Kim, YK; Kweon, GR; Lee, JU; Lee, MH; Lee, SE; Park, JH; Ryu, MJ; Shong, M | 1 |
| Bernardini, R; Duntas, LH | 1 |
| Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R | 1 |
| Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L | 1 |
| Takami, HE | 1 |
| Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L | 1 |
| Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S | 1 |
| Fernández-Contreras, ME; Hinojar-Gutiérrez, A; Mendoza, J; Mera-Menéndez, F; Moreno, R; Nieto-Llanos, S | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Couto, JP; Martins, TC; Prazeres, H; Rodrigues, F; Soares, P; Sobrinho-Simões, M; Torres, J; Trovisco, V; Vinagre, J | 1 |
| Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A | 1 |
| Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
| Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S | 1 |
| Geliebter, J; Moscatello, AL; Nowicki, TS; Schantz, S; Shin, E; Tiwari, RK | 1 |
| Brose, MS; Chung, J; Kalmus, J; Kappeler, C; Nutting, CM; Reike, G; Schlumberger, M; Sherman, SI; Shong, YK; Smit, JW | 1 |
| Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J | 1 |
| Caronia, LM; Phay, JE; Shah, MH | 1 |
| Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C | 1 |
| Capdevila, J; Corral, J; Grande, E; Grau, JJ; Halperin, I; Iglesias, L; Martínez-Trufero, J; Obiols, G; Segura, A; Tabernero, J; Vaz, MÁ | 1 |
| Meyer, P; Missana, A | 1 |
| Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
| Escobar-Jiménez, F; García-Martín, A; López-Ibarra Lozano, PJ; Triviño-Ibáñez, EM | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S | 1 |
| Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R | 1 |
| Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M | 1 |
| Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ | 1 |
| Dekkers, OM; Smit, JW; Verloop, H | 1 |
| Lin, CI; Lorch, JH; Ruan, DT; Whang, EE | 1 |
| Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN | 1 |
| An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z | 1 |
| Fagin, JA | 1 |
| Anaganti, S; Carlomagno, F; Guida, T; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM | 1 |
| Carlomagno, F; De Falco, V; Melillo, RM; Nappi, TC; Pepe, S; Salerno, P; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM | 1 |
| Calzada, G; El-Naggar, AK; Jasser, SA; Kim, S; Myers, JN; Wang, ZY; Yazici, YD; Younes, MN | 1 |
| Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L | 1 |
55 review(s) available for sorafenib and Thyroid Neoplasms
| Article | Year |
|---|---|
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2022 |
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives.
Topics: Adenocarcinoma, Follicular; Humans; Iodine Radioisotopes; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2022 |
State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2022 |
Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Topics: Aged; Carcinoma, Hepatocellular; Humans; Iodine Radioisotopes; Kidney Neoplasms; Liquid Biopsy; Liver Neoplasms; Male; Mutation; Proto-Oncogene Proteins B-raf; Quality of Life; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2022 |
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2022 |
Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.
Topics: Carcinoma; Humans; Immunocompromised Host; Sorafenib; Thyroid Neoplasms | 2022 |
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?
Topics: Humans; Imatinib Mesylate; Progression-Free Survival; Sorafenib; Thyroid Neoplasms; Tyrosine Kinase Inhibitors | 2023 |
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2023 |
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Iodine Radioisotopes; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2019 |
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Iodine Radioisotopes; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Sorafenib; Technology Assessment, Biomedical; Thyroid Neoplasms; United Kingdom | 2020 |
Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2020 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2020 |
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the 'real-world' experience?
Topics: Iodine Radioisotopes; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Radiation Tolerance; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2021 |
Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Sorafenib; Thyroid Neoplasms | 2021 |
Which patient with thyroid cancer deserves systemic therapy and when?
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Failure | 2017 |
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2017 |
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed | 2017 |
Sorafenib: key lessons from over 10 years of experience.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib; Thyroid Neoplasms | 2019 |
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Sorafenib; Thyroid Neoplasms | 2019 |
The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Immunotherapy; Iodine Radioisotopes; Middle Aged; Network Meta-Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Neoplasms | 2019 |
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Sorafenib in metastatic thyroid cancer: a systematic review.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2014 |
Sorafenib (Nexavar) for thyroid cancer.
Topics: Animals; Antineoplastic Agents; Dermatitis, Exfoliative; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Sorafenib for the treatment of thyroid cancer: an updated review.
Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Topics: Disease-Free Survival; Humans; Indoles; Iodine Radioisotopes; MAP Kinase Kinase Kinase 1; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Neoplasms | 2015 |
The discovery and development of sorafenib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Drug Approval; Drug Design; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2015 |
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Targeted therapies in advanced differentiated thyroid cancer.
Topics: Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Quinolines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms | 2015 |
Aggressive thyroid cancer: targeted therapy with sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Sorafenib; Thyroid Neoplasms | 2017 |
Sorafenib: 10 years after the first pivotal trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Publication Bias; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2015 |
Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2016 |
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2015 |
Selective use of sorafenib in the treatment of thyroid cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2016 |
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Topics: Antineoplastic Agents; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2016 |
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2016 |
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Topics: Benzenesulfonates; Biopsy, Needle; Humans; Isoquinolines; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Humans; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Role of BRAF in thyroid oncogenesis.
Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Treatment Outcome | 2011 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Mutation; Niacinamide; Oncogenes; Phenylurea Compounds; Phosphotransferases; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2004 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
22 trial(s) available for sorafenib and Thyroid Neoplasms
| Article | Year |
|---|---|
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Topics: Adenocarcinoma; Antineoplastic Agents; Cohort Studies; Humans; Iodine Radioisotopes; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2022 |
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Japan; Male; Neoplasm Grading; Niacinamide; Patient Dropouts; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Tumor Burden | 2017 |
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Radiation Tolerance; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2017 |
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Topics: Cell Differentiation; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Models, Biological; Neoplasm Staging; Progression-Free Survival; Sorafenib; Thyroid Neoplasms | 2019 |
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
Topics: Antineoplastic Agents; Benzimidazoles; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms; United Kingdom | 2019 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2014 |
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss | 2015 |
Phase II trial of sorafenib in advanced thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Phase II trial of sorafenib in metastatic thyroid cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2009 |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2009 |
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2010 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2011 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2011 |
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Blotting, Western; Carcinoma, Medullary; Case-Control Studies; Cell Transformation, Neoplastic; Cells, Cultured; Female; Germ-Line Mutation; Humans; Kidney; Luciferases; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Niacinamide; NIH 3T3 Cells; Pedigree; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Thyroid Neoplasms; Transcription Factor 4; Transcription Factors; Young Adult | 2011 |
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; United Kingdom; Young Adult | 2011 |
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome | 2011 |
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms | 2013 |
134 other study(ies) available for sorafenib and Thyroid Neoplasms
| Article | Year |
|---|---|
Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America.
Topics: Antineoplastic Agents; Humans; Latin America; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2021 |
Re-evaluation of the role of autophagy in thyroid cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cisplatin; Humans; Sorafenib; Thyroid Neoplasms | 2022 |
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Tyrosine kinase inhibitor treatment and long-term follow-up for metastatic malignant struma ovarii.
Topics: Adolescent; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Ovarian Neoplasms; Protein Kinase Inhibitors; Sorafenib; Struma Ovarii; Thyroid Neoplasms | 2022 |
ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Citrate (pro-S)-Lyase; Cell Line, Tumor; Humans; Sorafenib; Thyroid Neoplasms | 2022 |
Eugenol: A New Option in Combination Therapy with Sorafenib for the Treatment of Undifferentiated Thyroid Cancer.
Topics: Caspase 8; Cell Line, Tumor; Eugenol; Humans; Sorafenib; Thyroid Neoplasms | 2022 |
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Topics: Drug Monitoring; Feasibility Studies; Humans; Liver; Sorafenib; Thyroid Neoplasms | 2022 |
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.
Topics: Glucose; Humans; Immune Checkpoint Inhibitors; Immunity; Paclitaxel; RNA, Messenger; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Microenvironment | 2022 |
Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Humans; Male; Panobinostat; Sorafenib; Spheroids, Cellular; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2023 |
Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
Topics: Biomarkers; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphocytes; Neutrophils; Prognosis; Retrospective Studies; Sorafenib; Thyroid Neoplasms | 2023 |
Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis.
Topics: Adenosine Triphosphate; Aurora Kinase A; Cell Line, Tumor; Humans; Phosphofructokinase-2; Protein Kinase Inhibitors; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2023 |
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Endoplasmic Reticulum; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Metastatic diffuse follicular variant papillary thyroid cancer without cervical lymph node metastasis presenting with symptoms related to hypopituitarism.
Topics: Aged; Humans; Hypopituitarism; Iodine Radioisotopes; Lymphatic Metastasis; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2023 |
The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.
Topics: Adenocarcinoma; Antineoplastic Agents; Diarrhea; Female; Humans; Iodine Radioisotopes; Phenylurea Compounds; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2023 |
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tyrosine Kinase Inhibitors | 2023 |
Therapeutic inhibition of ATR in differentiated thyroid cancer.
Topics: Adenocarcinoma; Animals; Ataxia Telangiectasia Mutated Proteins; Humans; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2023 |
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Humans; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2023 |
Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2019 |
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Quinolines; Republic of Korea; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome | 2019 |
Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Topics: Aged; Drug Substitution; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Iodine Radioisotopes; Kidney Diseases; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Radiation Tolerance; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Thyroid Neoplasms | 2020 |
Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib; Thyroid Neoplasms | 2020 |
Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2020 |
Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan.
Topics: Antineoplastic Agents; China; Humans; Iodine Radioisotopes; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taiwan; Thyroid Neoplasms | 2021 |
Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Paclitaxel; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2020 |
Efficacy of adavosertib therapy against anaplastic thyroid cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice; Pyrazoles; Pyrimidinones; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2021 |
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Topics: Aged; Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality of Life; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Tumor Burden; United States | 2017 |
Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2017 |
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Topics: Adenylyl Cyclases; Cell Differentiation; Cell Proliferation; Colforsin; Cyclic AMP; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured | 2017 |
Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Progression-Free Survival; Republic of Korea; Retrospective Studies; Sorafenib; Survival Analysis; Survival Rate; Tertiary Healthcare; Thyroid Neoplasms; Treatment Outcome | 2018 |
A whole-animal platform to advance a clinical kinase inhibitor into new disease space.
Topics: Animals; Animals, Genetically Modified; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Drosophila; Drug Design; Female; HCT116 Cells; Humans; Male; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Neoplasm Transplantation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2018 |
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Topics: Butadienes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mitogen-Activated Protein Kinases; Models, Biological; Nitriles; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Transcription Factors; Transcriptional Activation; Up-Regulation; Vemurafenib | 2018 |
First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Progression-Free Survival; Sorafenib; Thyroid Neoplasms | 2019 |
Number needed to treat in indirect treatment comparison.
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Numbers Needed To Treat; Phenylurea Compounds; Quinolines; Sorafenib; Statistics as Topic; Thyroid Neoplasms | 2018 |
A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adolescent; Adult; Aged; Antineoplastic Agents; Case-Control Studies; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Isoflavones; Male; Middle Aged; Receptors, Calcitriol; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Vitamin D; Young Adult | 2018 |
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Topics: Aged; Antineoplastic Agents; Drug Substitution; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Phosphorylation; Pyrimidines; Signal Transduction; Sorafenib; Sulfoxides; Thyroid Neoplasms | 2018 |
Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Indazoles; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Radiotherapy, Intensity-Modulated; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2018 |
Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
Topics: Abdomen; Aged; Carcinoma; Carcinoma, Hepatocellular; Folliculitis; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Skin Diseases; Sorafenib; Thigh; Thyroid Neoplasms | 2018 |
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Iodine Radioisotopes; Mice, Nude; Nanoparticles; Porosity; Receptors, Transferrin; Signal Transduction; Silicon Dioxide; Sorafenib; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Thyroid Neoplasms | 2019 |
Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
Topics: Databases, Factual; Drug Utilization Review; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; United States | 2019 |
Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Division; Cell Proliferation; Chemotherapy, Adjuvant; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2019 |
Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Molecular Targeted Therapy; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis; Thyroid Neoplasms | 2019 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Hidradenitis suppurativa associated with sorafenib initiation.
Topics: Adult; Antineoplastic Agents; Axilla; Deprescriptions; Hidradenitis Suppurativa; Humans; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2019 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Sorafenib makes headway on metastatic thyroid cancer.
Topics: Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
Topics: ACTH Syndrome, Ectopic; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary-Adrenal System; Sorafenib; Thyroid Neoplasms | 2014 |
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary, Follicular; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2014 |
More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2014 |
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pleural Effusion, Malignant; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
New era for treatment in differentiated thyroid cancer.
Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2014 |
Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Stroke Volume; Thyroid Neoplasms; Treatment Outcome | 2014 |
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure | 2015 |
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2014 |
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Thyroid Neoplasms; Thyroidectomy; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Topics: Antineoplastic Agents; Chemoradiotherapy; Evidence-Based Medicine; Germany; Humans; Iodine Radioisotopes; Medical Oncology; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2015 |
Thyroid carcinoma, version 2.2014.
Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms | 2014 |
The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib; Thyroid Neoplasms; Two-Dimensional Difference Gel Electrophoresis; Up-Regulation; Voltage-Dependent Anion Channel 2; Young Adult | 2015 |
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Metformin; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sorafenib; Spheroids, Cellular; Thyroid Neoplasms; Tumor Stem Cell Assay | 2015 |
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
Topics: Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Liver; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2015 |
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Iodide Peroxidase; Iron-Binding Proteins; Microfilament Proteins; Muscle Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Thyrotropin; Signal Transduction; Sorafenib; Symporters; Thyroid Neoplasms | 2015 |
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
Sorafenib in the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Immunoblotting; Interferon-alpha; Interleukin-2; Janus Kinase 1; K562 Cells; Leukocytes, Mononuclear; Lymphocytes; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; STAT1 Transcription Factor; STAT5 Transcription Factor; Thyroid Neoplasms | 2015 |
[Molecular targeting treatment for thyroid cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Curcumin; Dose-Response Relationship, Drug; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2016 |
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2015 |
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Syndrome; Diabetes Insipidus; Fatal Outcome; Humans; Hydrocortisone; Intussusception; Jejunal Diseases; Male; Niacinamide; Paraneoplastic Polyneuropathy; Phenylurea Compounds; Primary Dysautonomias; Sorafenib; Thyroid Neoplasms | 2015 |
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2015 |
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Outcome | 2016 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2016 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms | 2016 |
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2016 |
Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2016 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinacrine; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Transcription Factor RelA | 2016 |
Efficacy of lenvatinib in treating thyroid cancer.
Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2016 |
68Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib.
Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2016 |
[Lenvatinib in radioiodine refractory thyroid carcinomas].
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trials; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2016 |
Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Choroid Neoplasms; Female; Goiter, Nodular; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2017 |
Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Failure | 2017 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2008 |
Sorafenib-induced liver failure.
Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Failure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2009 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms | 2010 |
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2009 |
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Endocytosis; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Lymph Node Excision; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2010 |
Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2011 |
Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Humans; Mice; Mice, Transgenic; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Subcellular Fractions; Thyroid Gland; Thyroid Neoplasms | 2011 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outcome; Humans; Imatinib Mesylate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiography; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2011 |
A painful cranial bulge.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Embolization, Therapeutic; Humans; Laryngeal Neoplasms; Laryngectomy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Thyroidectomy | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms | 2012 |
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms; Urokinase-Type Plasminogen Activator | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary | 2012 |
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Sirolimus; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2012 |
Sorafenib in metastatic thyroid cancer.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2012 |
[Endocrinology].
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clinical Trials as Topic; Endocrine Gland Neoplasms; Endocrinology; Humans; Niacinamide; Phenylurea Compounds; Pituitary ACTH Hypersecretion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptors, Somatostatin; Somatostatin; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2013 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2013 |
Sorafenib therapy decreases the clearance of thyrotropin.
Topics: Aged; Aged, 80 and over; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Function Tests; Thyroid Neoplasms; Thyrotropin | 2013 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms | 2012 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides | 2012 |
[Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Liposomes; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
BAY 43-9006 inhibition of oncogenic RET mutants.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Drug Administration Schedule; Enzyme Inhibitors; Fibroblasts; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Phosphotransferases; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib; Thyroid Neoplasms; Transfection; Transplantation, Heterologous | 2006 |
BRAF is a therapeutic target in aggressive thyroid carcinoma.
Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Transplantation, Heterologous | 2006 |
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Benzenesulfonates; Cell Division; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Transplantation, Heterologous | 2007 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms | 2008 |